J 2018

Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

GAYAT, Etienne, Mattia ARRIGO, Simona LITTNEROVÁ, Naoki SATO, Jiří PAŘENICA et. al.

Základní údaje

Originální název

Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

Autoři

GAYAT, Etienne (250 Francie, garant), Mattia ARRIGO (756 Švýcarsko), Simona LITTNEROVÁ (203 Česká republika, domácí), Naoki SATO (392 Japonsko), Jiří PAŘENICA (203 Česká republika, domácí), Shiro ISHIHARA (392 Japonsko), Jindřich ŠPINAR (203 Česká republika, domácí), Christian MULLER (756 Švýcarsko), Veli-Pekka HARJOLA (246 Finsko), Johan LASSUS (246 Finsko), Oscar MIRO (724 Španělsko), Aldo P. MAGGIONI (380 Itálie), Khalid F. ALHABIB (682 Saúdská Arábie), Dong-Ju CHOI (410 Korejská republika), Jin Joo PARK (410 Korejská republika), Yuhui ZHANG (156 Čína), Jian ZHANG (156 Čína), James L., Jr. JANUZZI (840 Spojené státy), Katsuya KAJIMOTO (392 Japonsko), Alain COHEN-SOLAL (250 Francie) a Alexandre MEBAZAA (250 Francie)

Vydání

European Journal of heart Failure, Hoboken, Wiley, 2018, 1388-9842

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 12.129

Kód RIV

RIV/00216224:14110/18:00102127

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000429044500022

Klíčová slova anglicky

Acute heart failure; Prognosis; Oral therapy

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 10. 2. 2019 13:24, Soňa Böhmová

Anotace

V originále

Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient's condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.& para;& para;Methods and results The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary and results outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.& para;& para;Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.

Návaznosti

MUNI/A/1365/2015, interní kód MU
Název: Kardiovaskulární systém: od modelu přes terapii k prevenci (Akronym: KAMOTEPRE)
Investor: Masarykova univerzita, Kardiovaskulární systém: od modelu přes terapii k prevenci, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty